vonoprazan fumarate · Phathom · NDA 215151
Voquezna
Earliest generic entry, as listed · earliest of 2 marketed strengths
3 May 2032
Blocked by exclusivity: GAIN.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9186411 | product | 11 Aug 2030 |
| US 7977488 | substance | 10 Apr 2030 |
Exclusivities · 4 unexpired
| GAIN | qualified infectious disease product | 3 May 2032 |
| I-948 | new indication (3 years) | 17 Jul 2027 |
| NCE | new chemical entity (5 years) | 3 May 2027 |
| NP | new product | 1 Nov 2026 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Exclusivity expires within 90 days NP · 215151-0021 Nov 2026
- 24 Oct 2026Exclusivity expires within 90 days NP · 215151-0011 Nov 2026
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215151 · 001 · RLD | tablet, oral | EQ 10MG BASE | 3 May 2032 |
| 215151 · 002 · RLD | tablet, oral | EQ 20MG BASE | 3 May 2032 |